CA9 and glioblastoma: Acetazolamide reduces the production of cerebrospinal fluid (CSF) and is used clinically for this purpose [49], thus forming another potential benefit for the use of CA IX inhibitors like zonisamide during glioblastoma treatment, in addition to the potential augmentation of bevacizumab.